Hikma Pharmaceuticals Plc (LON:HIK) Receives “Reduce” Rating from HSBC Holdings plc

HSBC Holdings plc reissued their reduce rating on shares of Hikma Pharmaceuticals Plc (LON:HIK) in a research report released on Tuesday, July 4th, StockTargetPrices.com reports. HSBC Holdings plc currently has a GBX 1,800 ($23.45) target price on the stock.

A number of other brokerages have also issued reports on HIK. J P Morgan Chase & Co lowered Hikma Pharmaceuticals Plc to a neutral rating and increased their price objective for the stock from GBX 2,100 ($27.36) to GBX 2,400 ($31.27) in a report on Thursday, March 16th. Peel Hunt reissued a buy rating and issued a GBX 2,340 ($30.48) price objective on shares of Hikma Pharmaceuticals Plc in a report on Wednesday, March 15th. Numis Securities Ltd lowered Hikma Pharmaceuticals Plc to an add rating and set a GBX 2,350 ($30.61) price objective for the company. in a report on Friday, March 10th. Finally, Stifel Nicolaus reissued a buy rating and issued a GBX 2,550 ($33.22) price objective on shares of Hikma Pharmaceuticals Plc in a report on Tuesday, April 4th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of GBX 1,996.10 ($26.00).

Hikma Pharmaceuticals Plc (LON:HIK) opened at 1399.00 on Tuesday. The stock’s market capitalization is GBX 3.37 billion. Hikma Pharmaceuticals Plc has a 12-month low of GBX 1,339.50 and a 12-month high of GBX 2,703.00. The company has a 50 day moving average of GBX 1,485.13 and a 200-day moving average of GBX 1,814.91.

ILLEGAL ACTIVITY NOTICE: “Hikma Pharmaceuticals Plc (LON:HIK) Receives “Reduce” Rating from HSBC Holdings plc” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/07/30/hikma-pharmaceuticals-plcs-lonhik-reduce-rating-reaffirmed-at-hsbc-holdings-plc-updated-updated-updated.html.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Stock Target Prices

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply